This month's mag takes the relentless tittle-tattle from 'influencers' about GLP-1 before scrutinizing, deconstructing and ...
IMAAVY has become the first FDA‑approved therapy for warm autoimmune haemolytic anaemia, offering a targeted approach ...
Nxera Pharma has announced that its partner Neurocrine Biosciences has received FDA IND acceptance for a phase 2 study of NBI‑1117567 for Alzheimer’s cognition. Nxera will rec ...
A July 2026 Leerink Partners report named Carterra a core enabling technology in the growing Lab‑in‑the‑Loop market. The ...
GSK has announced that the US FDA has accepted for priority review a supplemental Biologics License Application for Jemperli ...
Avulux has received De Novo marketing authorisation from the FDA, establishing the first recognised device classification for ...
Erasca has been granted Fast Track Designation by the FDA for ERAS‑0015, an oral pan‑RAS molecular glue being developed for ...
FairJourney Bio has published a peer‑reviewed study in mAbs describing a novel antibody‑engineering approach designed to ...
Teva Pharmaceuticals has announced that the US Food and Drug Administration has accepted the new drug application for ...
HUTCHMED has reported positive high‑level results from the Saffron phase 3 trial evaluating Orpathys (savolitinib) plus ...
The MHRA’s position is that MBMPs fall within the scope of the existing UK medicines regulatory framework set out in the ...
AC Immune has announced encouraging preliminary findings from its phase 1 first‑in‑human study of ACI‑19764, an orally ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results